These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16093276)

  • 21. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).
    Eich HT; Müller RP; Engenhart-Cabillic R; Lukas P; Schmidberger H; Staar S; Willich N;
    Strahlenther Onkol; 2008 Aug; 184(8):406-10. PubMed ID: 18956517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
    Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
    Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control.
    Mendenhall NP; Rodrigue LL; Moore-Higgs GJ; Marcus RB; Million RR
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):551-61. PubMed ID: 10348284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment results of Hodgkin's lymphoma].
    Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
    Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.
    Hoskin PJ; Smith P; Maughan TS; Gilson D; Vernon C; Syndikus I; Linch DC;
    Clin Oncol (R Coll Radiol); 2005 Feb; 17(1):47-53. PubMed ID: 15714929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
    Rüffer JU; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A;
    Leuk Lymphoma; 2005 Nov; 46(11):1561-7. PubMed ID: 16236610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
    Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
    Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968-1980).
    Cornbleet MA; Vitolo U; Ultmann JE; Golomb HM; Oleske D; Griem ML; Ferguson DJ; Miller JB
    J Clin Oncol; 1985 Jun; 3(6):758-68. PubMed ID: 4009215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tirelli U; Bortolus R; van 't Veer MB; Lybeert ML; Keuning JJ; Carde P; Girinsky T; van der Maazen RW; Tomsic R; Vovk M; van Hoof A; Demeestere G; Lugtenburg PJ; Thomas J; Schroyens W; De Boeck K; Baars JW; Kluin-Nelemans JC; Carrie C; Aoudjhane M; Bron D; Eghbali H; Smit WG; Meerwaldt JH; Hagenbeek A; Pinna A; Henry-Amar M;
    N Engl J Med; 2003 Jun; 348(24):2396-406. PubMed ID: 12802025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Retrospective analysis for 104 cases of early-stage Hodgkin's Lymphoma treated with different modality therapies].
    Du TT; Xiao XB; Su H; Da Y; Chen XL; Zhong KL; Zhao SH; Lu Y; Wang S; Zhang WJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):320-4. PubMed ID: 22541090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors.
    Liao Z; Ha CS; Fuller LM; Hagemeister FB; Cabanillas F; Tucker SL; Hess MA; Cox JD
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1047-56. PubMed ID: 9719114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Younes A; Fayad L; Rodriguez MA; Hagemeister FB; Barista I; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):36-43. PubMed ID: 12504034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.